Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch
Questions Over Phase I Adverse Event
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
